Bevacizumab in recurrent high-grade pediatric gliomas

Neuro-Oncology

Volumn 12, Issue 9, 2010, Pages 985-990

  Narayana, Ashwatha ^a,b   Kunnakkat, Saroj ^a   Chacko Mathew, Jeena ^a   Gardner, Sharon ^a   Karajannis, Matthias ^a   Raza, Shahzad ^a   Wisoff, Jeffrey ^b   Weiner, Howard ^b   Harter, David ^b   Allen, Jeffrey ^a  

^a Department of Radiation Oncology ^*  (United States)

^b NEW YORK UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

Antiangiogenic therapy; Bevacizumab; Highgrade glioma

Indexed keywords

BEVACIZUMAB; IRINOTECAN;

ADOLESCENT; ADULT; ANAPHYLAXIS; ARTICLE; BLEEDING; CANCER GRADING; CANCER GROWTH; CANCER RECURRENCE; CANCER RELAPSE; CANCER SURVIVAL; CHILD; CHILDHOOD CANCER; CLINICAL ARTICLE; CONSTIPATION; DEEP VEIN THROMBOSIS; DIARRHEA; DIFFUSE INTRINSIC PONTINE GLIOMA; DRUG TOLERABILITY; DRUG WITHDRAWAL; FEMALE; GLIOMA; HUMAN; MALE; NAUSEA; NUCLEAR MAGNETIC RESONANCE IMAGING; PATIENT COMPLIANCE; PRESCHOOL CHILD; RASH; SCHOOL CHILD; TREATMENT RESPONSE; VOMITING;

ADOLESCENT; ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BRAIN NEOPLASMS; CAMPTOTHECIN; CHILD; CHILD, PRESCHOOL; DISEASE-FREE SURVIVAL; FEMALE; GLIOMA; HUMANS; KAPLAN-MEIER ESTIMATE; MAGNETIC RESONANCE IMAGING; MALE; NEOPLASM RECURRENCE, LOCAL; RETROSPECTIVE STUDIES; SALVAGE THERAPY; YOUNG ADULT;

EID: 77954134452     PISSN: 15228517     EISSN: 15235866     Source Type: Journal    
DOI: 10.1093/neuonc/noq033     Document Type: Article

References (23)

1. Halperin E, Constine L, Tarbell N, Kun L. Pediatric Radiation Oncology. 4th ed. Philadelphia: Lippincott Williams & Wilkins; 2004.
2. Mueller S, Chang S. Pediatric brain tumors: current treatment strategies and future therapeutic approaches. Neurotherapeutics. 2009;6(3): 570-586.
3. Hurwitz H, Fehrenbacher L, Novotny W, et al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med. 2004;350(23):2335-2342.
4. Traina TA, Rugo HS, Dickler M. Bevacizumab for advanced breast cancer. Hematology/Oncology Clinics of North America. 2007;21(2): 303-319.
5. Johnson DH, Fehrenbacher L, Novotny WF, et al. Randomized Phase II Trial comparing bevacizumab plus carboplatin and paclitaxel with carboplatin and paclitaxel alone in previously untreated locally advanced or metastatic non-small-cell lung cancer. J Clin Oncol. 2004;22(11): 2184-2191.
6. Escudier B, Cosaert J, Jethwa S. Targeted therapies in the management of renal cell carcinoma: role of bevacizumab. Biologics. 2008;2(3): 517-530.
7. Vredenburgh JJ, Desjardins A, Herndon JE, 2nd, et al. Phase II trial of bevacizumab and irinotecan in recurrent malignant glioma. Clin Cancer Res. 2007;13(4):1253-1259.
8. Chen W, Delaloye S, Silverman DHS, et al. Predicting treatment response of malignant gliomas to bevacizumab and irinotecan by imaging proliferation with [18F] fluorothymidine positron emission tomography: a Pilot Study. J Clin Oncol. 2007;25(30):4714-4721.
9. Friedman HS, Prados MD, Wen PY, et al. Bevacizumab alone and in combination with irinotecan in recurrent glioblastoma. J Clin Oncol. 2009;27(28):4733-4740.
10. Narayana A, Kelly P, Golfinos J, et al. Antiangiogenic therapy using bevacizumab in recurrent high-grade glioma: impact on local control and patient survival. J Neurosurg. 2009;110(1):173-180.
11. Gruber ML, Buster WP. Temozolomide in combination with irinotecan for treatment of recurrent malignant glioma. Am J Clin Oncol. 2004;27(1):33-38.
12. Torcuator R, Zuniga R, Loutfi R, Mikkelsen T. Bevacizumab and irinotecan treatment for progressive diffuse brainstem glioma: case report. J Neurooncol. 2009;93(3):409-412.
13. Packer RJ, Jakacki R, Horn M, et al. Objective response of multiply recurrent low-grade gliomas to bevacizumab and irinotecan. Pediatric Blood Cancer. 2009;52(7):791-795.
14. Norden AD, Young GS, Setayesh K, et al. Bevacizumab for recurrent malignant gliomas: Efficacy, toxicity, and patterns of recurrence. Neurology. 2008;70(10):779-787.
15. Narayana A, Golfinos JG, Fischer I, et al. Feasibility of using bevacizumab with radiation therapy and temozolomide in newly diagnosed high-grade glioma. Int J Radiat Oncol Biol Phys. 2008;72(2):383-389.
16. Parekh C, Jubran R, Finlay JL, Dhall G. Treatment of children with recurrent or progressive high-grade gliomas with irinotecan, temozolomide,and bevacizumab [abstract]. In: Abstracts for the Thirteenth AnnualMeeting of the Society for Neuro-Oncology. Neuro-Oncology. 2008. 10(5):759-915.
17. Gururangan S, Chi S, Onar A, et al. Phase II study of bevacizumab plus irinotecan in children with recurrent malignant glioma and diffuse brainstem glioma-a Pediatric Brain Tumor Consortium study (PBTC-022) [abstract]. In: Abstracts for the Thirteenth Annual Meeting of the Society for Neuro-Oncology. Neurooncology. 2008. 10(5):759-915.
18. Rickert CH, Strater R, Kaatsch P, et al. Pediatric High-grade astrocytomas show chromosomal imbalances distinct from adult cases. Am J Pathol. 2001;158(4):1525-1532.
19. Pfister S, Hartmann C, Korshunov A. Histology and molecular pathology of pediatric brain tumors. J Child Neurol. 2009;24(11):1375-1386.
20. Sung T, Miller DC, Hayes RL, Alonso M, Yee H, Newcomb EW. Preferential inactivation of the p53 tumor suppressor pathway and lack of EGFR amplification distinguish de novo high grade pediatric astrocytomas from de novo adult astrocytomas. Brain Pathol. 2000; 10(2):249-259.
21. Nghiemphu PL, Liu W, Lee Y, et al. Bevacizumab and chemotherapy for recurrent glioblastoma: A single-institution experience. Neurology. 2009;72(14):1217-1222.
22. Pollack IF, Finkelstein SD, Burnham J, et al. Association between chromosome 1p and 19q loss and outcome in pediatric malignant gliomas: results from the CCG-945 cohort. Pediatr Neurosurg. 2003; 39(3):114-121.
23. Bartels U, Hawkins C, Ma J, et al. Vascularity and angiogenesis as predictors of growth in optic pathway/hypothalamic gliomas. J Neurosurg: Pediatrics. 2006;104(5):314-320.